Orphan

Identifikatoren & physikalische Daten

CAS No.	297-90-5
Summenformel	C17H23NO
Durchschnittliche Molmasse	257,37 g/mol
Monoisotopische Masse	257,17796436 g/mol
SMILES	CN1CCC23CCCCC2C1Cc1ccc(O)cc13
InChIKey	JAQUASYNZVUNQP-UHFFFAOYSA-N
PubChem CID	3918
ChEMBL	CHEMBL20803
EC No.	206-048-0

Chemische & physikalische Eigenschaften

XLogP	3,1
Polarare Oberfläche (TPSA)	23,5
H-Brücken-Donoren	1
H-Brücken-Akzeptoren	2
Frei drehbare Bindungen	0
Schwere Atome	19
Formalladung	0
Komplexität	357
Arzneimittel	DEA NFLIS-Drug Category -> Narcotic AnalgesicsDEA Schedule II Controlled Substance -> Opiates

Sicherheit & Vorschriften

Regulatorische Informationen	DEA schedule II controlled substance
Treatment	The specific treatment of suspected levorphanol tartrate overdosage is immediate establishment of an adequate airway and ventilation, followed (if necessary) by intravenous naloxone. The respiratory and cardiac status of the patient should be continuously monitored and appropriate supportive measures instituted, such as oxygen, intravenous fluids and/or vasopressors, if required. Physicians are reminded that the duration of levorphanol action far exceeds the duration of action of naloxone, and repeated dosing with naloxone may be required. Naloxone should be administered cautiously to persons known or suspected to be physically dependent on Levorphanol. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute abstinence syndrome. If necessary to administer naloxone to the physically dependent patient, the antagonist should be administered with extreme care and by titration with smaller than usual doses of the antagonist. (L1712)
Gesundheitliche Auswirkungen	Medical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.
Expositionspfade	Subcutaneous, Intravenous, or Intramuscular injectionOral. Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.
Toxizitätsübersicht	Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.
Signs and Symptoms	Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.
Carcinogen Classification	No indication of carcinogenicity to humans (not listed by IARC).
Toxicity Data	LD50: 150 mg/kg (Oral, Rat) (A308)

CAS No.

297-90-5

Summenformel

C17H23NO

Durchschnittliche Molmasse

257,37 g/mol

Monoisotopische Masse

257,17796436 g/mol

SMILES

CN1CCC23CCCCC2C1Cc1ccc(O)cc13

InChIKey

JAQUASYNZVUNQP-UHFFFAOYSA-N

PubChem CID

3918

ChEMBL

CHEMBL20803

EC No.

206-048-0

XLogP

3,1

Polarare Oberfläche (TPSA)

23,5

H-Brücken-Donoren

H-Brücken-Akzeptoren

Frei drehbare Bindungen

Schwere Atome

Formalladung

Komplexität

357

Arzneimittel

DEA NFLIS-Drug Category -> Narcotic AnalgesicsDEA Schedule II Controlled Substance -> Opiates

Sicherheit & Vorschriften

Regulatorische Informationen

DEA schedule II controlled substance

Treatment

The specific treatment of suspected levorphanol tartrate overdosage is immediate establishment of an adequate airway and ventilation, followed (if necessary) by intravenous naloxone. The respiratory and cardiac status of the patient should be continuously monitored and appropriate supportive measures instituted, such as oxygen, intravenous fluids and/or vasopressors, if required. Physicians are reminded that the duration of levorphanol action far exceeds the duration of action of naloxone, and repeated dosing with naloxone may be required. Naloxone should be administered cautiously to persons known or suspected to be physically dependent on Levorphanol. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute abstinence syndrome. If necessary to administer naloxone to the physically dependent patient, the antagonist should be administered with extreme care and by titration with smaller than usual doses of the antagonist. (L1712)

Gesundheitliche Auswirkungen

Medical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.

Expositionspfade

Subcutaneous, Intravenous, or Intramuscular injectionOral. Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.

Toxizitätsübersicht

Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.

Signs and Symptoms

Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.

Carcinogen Classification

No indication of carcinogenicity to humans (not listed by IARC).

Toxicity Data

LD50: 150 mg/kg (Oral, Rat) (A308)